Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports first-quarter revenues of over $1 billion.
You may also be interested in...
Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.
Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.
Merck’s Novel HIV Drug Isentress Granted Six-Month FDA Review
First-in-class integrase inhibitor could see a mid-October approval.